Division of Strategic Planning and Evaluation Drug Discovery Support Network (DDSN)

Outline

Key Fields Drug Discovery & Development(1st)
R&D phase Basic Study, Applied Study, Nonclinical Study/Pre-clinical Study, Clinical Study, Clinical Trials, Post Marketing, Clinical Research, None

Overview

The Drug Discovery Support Network (DDSN) is a collaborative framework that pulls together 3 public research organizations, i.e., RIKEN, the National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), and the National Institute of Advanced Industrial Science (AIST), to contribute to the iD3 Booster program by providing with their cutting edge technologies for high throughput screening (HTS) and lead optimization and characterization, spanning various drug modalities, including small molecular synthetic compounds, natural compounds, monoclonal antibodies and nucleic acids. Since the DDSN was established in 2013, AMED iD3 has been performing a headquarters function to ensure smooth and productive collaboration amongst the 3 institutions concerned.
 

Contact

Department of Innovative Drug Discovery and Development
 (East Japan Office) Tel : +81-3-3516-6181
 (West Japan Office) Tel : +81-6-6372-1771

Last updated 10/27/17